Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642439 | 0.87 | MEN1 (0.71) | KMT2AMEN1HTTTP53RXFP1 | |
| SCHEMBL14773191 | 0.81 | GRM4 (0.68) | KMT2AMEN1HTTMAPTGAA | |
| SCHEMBL13679551 | 0.76 | MEN1 (0.69) | KMT2AMEN1HTTTP53RXFP1 | |
| SCHEMBL14642442 | 0.74 | MEN1 (0.79) | KMT2AMEN1HTTTP53RXFP1 | |
| SCHEMBL13679581 | 0.74 | MEN1 (0.69) | KMT2AMEN1HTTTP53RXFP1 | |
| SCHEMBL14773186 | 0.74 | SMN1; SMN2 (0.57) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL14642443 | 0.74 | MEN1 (0.72) | KMT2AMEN1HTTTP53RXFP1 | |
| SCHEMBL13679609 | 0.74 | TP53 (0.68) | KMT2AMEN1HTTTP53RXFP1 | |
| SCHEMBL13679611 | 0.73 | MEN1 (0.74) | KMT2AMEN1HTTTP53RXFP1 | |
| SCHEMBL15424140 | 0.72 | MEN1 (0.73) | KMT2AMEN1HTTTP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309237-B2 | HIV inhibitors | NEW YORK BLOOD CENTER, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140377219-A1 | HIV INHIBITORS | NEW YORK BLOOD CENTER, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2013036676-A1 | HIV INHIBITORS | NEW YORK BLOOD CENTER, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377219-A1 | HIV INHIBITORS | MAVS, CD4, SARS1 | KMT2A 1491/4885MEN1 4122/4885HTT 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.